Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults

Vaccine

Volumn 33, Issue 9, 2015, Pages 1151-1159

  Gorse, Geoffrey J ^a   Falsey, Ann R ^b   Ozol Godfrey, Ayca ^c   Landolfi, Victoria ^c   Tsang, Peter H ^c  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c SANOFI PASTEUR   (France)

Author keywords

Adults; ClinicalTrials.gov no. NCT01712984; Immunogenicity; Intradermal; Phase III; Quadrivalent influenza vaccine; Safety

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE; INACTIVATED VACCINE; VIRUS ANTIBODY;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BELL PALSY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG SAFETY; ECCHYMOSIS; FEMALE; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; MYELITIS; OPTIC NEURITIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; ADOLESCENT; BLOOD; CLINICAL TRIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA VACCINES; INJECTIONS, INTRADERMAL; MALE; MIDDLE AGED; UNITED STATES; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 84922816378     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.01.025     Document Type: Article

References (18)

1. Durando P., Iudici R., Alicino C., Alberti M., Florentiis D.D., Ansaldi F., et al. Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine. Hum Vaccin 2011, 7:29-40. Suppl.
2. Gorse G.J., Falsey A.R., Fling J.A., Poling T.L., Strout C.B., Tsang P.H. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age. Vaccine 2013, 31:2358-2365.
3. Gorse G.J., Falsey A.R., Johnson C.M., Morrison D., Fried D.L., Ervin J.E., et al. Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age. Vaccine 2013, 31:6034-6040.
4. Glezen W.P., Schmier J.K., Kuehn C.M., Ryan K.J., Oxford J. The burden of influenza B: a structured literature review. Am J Public Health 2013, 103:e43-e51.
5. Centers for Disease Control Past Weekly Surveillance Reports 2014, Centers for Disease Control.
6. Reed C., Meltzer M.I., Finelli L., Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 2012, 30:1993-1998.
7. Greenberg D.P., Robertson C.A., Noss M.J., Blatter M.M., Biedenbender R., Decker M.D. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine 2013, 31:770-776.
8. Center for Biologics Evaluation and Research Guidance for industry. Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines 2007, Center for Biologics Evaluation and Research, Silver Spring, MD.
9. Keitel W.A., Cate T.R., Couch R.B., Huggins L.L., Hess K.R. Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period. Vaccine 1997, 15:1114-1122.
10. Sasaki S., He X.S., Holmes T.H., Dekker C.L., Kemble G.W., Arvin A.M., et al. Influence of prior influenza vaccination on antibody and B-cell responses. PLoS ONE 2008, 3:e2975.
11. Levandowski R.A., Regnery H.L., Staton E., Burgess B.G., Williams M.S., Groothuis J.R. Antibody responses to influenza B viruses in immunologically unprimed children. Pediatrics 1991, 88:1031-1036.
12. Parodi V., de Florentiis D., Martini M., Ansaldi F. Inactivated influenza vaccines: recent progress and implications for the elderly. Drugs Aging 2011, 28:93-106.
13. Beyer W.E., Palache A.M., Kerstens R., Masurel N. Gender differences in local and systemic reactions to inactivated influenza vaccine, established by a meta-analysis of fourteen independent studies. Eur J Clin Microbiol Infect Dis 1996, 15:65-70. (official publication of the European Society of Clinical Microbiology).
14. Govaert T.M., Dinant G.J., Aretz K., Masurel N., Sprenger M.J., Knottnerus J.A. Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial. BMJ 1993, 307:988-990.
15. Jackson L.A., Austin G., Chen R.T., Stout R., DeStefano F., Gorse G.J., et al. Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors. Vaccine 2001, 19:4703-4709.
16. Masurel N., Laufer J. A one-year study of trivalent influenza vaccines in primed and unprimed volunteers: immunogenicity, clinical reactions and protection. J Hyg 1984, 92:263-276.
17. Nichol K.L., Margolis K.L., Lind A., Murdoch M., McFadden R., Hauge M., et al. Side effects associated with influenza vaccination in healthy working adults. A randomized, placebo-controlled trial. Arch Intern Med 1996, 156:1546-1550.
18. Dinleyici E.C. Current status of pneumococcal vaccines: lessons to be learned and new insights. Expert Rev Vaccines 2010, 9:1017-1022.